Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients
By Nikita Chaurasia  Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
By Nikita Chaurasia

  The company has reportedly ceased its operations after 2453 employees tested positive for the Coronavirus. The company’s shares plummeted by 7.5% after the Malaysian government ordered to shut down 28 of its factories. As per relia...

Belcan becomes software engineering services firm Avista’s new owner
Belcan becomes software engineering services firm Avista’s new owner
By Nikita Chaurasia

Belcan, LLC, a leading supplier of engineering, technical recruiting, supply chain, and information technology (IT) services to various sectors, reportedly announced the acquisition of Avista, Inc., a safety-critical and mission-critical software eng...

Swisscom to install Nokia FastMile 5G Receivers in Switzerland
Swisscom to install Nokia FastMile 5G Receivers in Switzerland
By Nikita Chaurasia

Nokia, the leading Finnish telecommunications giant, has reportedly announced that Swisscom, a renowned Swiss telecommunications firm, would install Nokia FastMile 5G Receivers across rural areas of Switzerland to provide high speed broadband service...

CDC funds $1.5 Mn for co-robots; aims to reduce worker exposure
CDC funds $1.5 Mn for co-robots; aims to reduce worker exposure
By Nikita Chaurasia

Projects developed through this grant is expected to be used in developing collaborative robots for use in the manufacturing and healthcare industries. With over more than 5000 workers losing their lives due to work-related injury in the United ...

Telia & Ericsson join hands to launch Estonia’s first 5G network
Telia & Ericsson join hands to launch Estonia’s first 5G network
By Nikita Chaurasia

Telia, a Swedish multinational telecommunications company, will be the first one to begin 5G in the country which will be powered by Ericsson 5G technology. With this move, the company will be enabling innovation for businesses and provide high-speed...